ABC.L Regulatory News (ABC)

ABCAM PLC

("Abcam" or "the Company")

Analyst Site Visit

Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, is today hosting a site visit for analysts at its headquarters in Cambridge, UK.

The visit will focus on operational aspects of the Company and will include presentations by executives including Jim Warwick, Chief Operating Officer. The visit will include a tour of the Company's headquarters building and nearby production facility, both of which are located at the Cambridge Science Park.

No new material information will be disclosed.

For further information please contact:

Abcam + 44 (0) 1223 696000

Jonathan Milner, Chief Executive Officer

Jeff Iliffe, Chief Financial Officer

www.abcamplc.com

Numis Securities + 44 (0) 20 7260 1000

Michael Meade / Nick Westlake - Nominated Adviser

James Black - Corporate Broking

Buchanan Communications + 44 (0) 20 7466 5000

Mark Court / Jessica Fontaine

Notes for editors

About Abcam plc

Abcam is a producer and distributor of research-grade antibodies and related products, headquartered in Cambridge, United Kingdom, with US offices in Cambridge, Massachusetts, and San Francisco, California, and Far East offices in Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party products to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All products are sold under the Abcam brand name and the Company's vision is to build the world's largest online resource of high-quality and commercially viable antibodies. Abcam now has an online catalogue of over 66,000 products, most of which are antibodies, from over 250 suppliers and employs 270 staff.